Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.47 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619410 | 0.99 | MCHR1 (0.47) | HTR2AHTR2CMCHR1ASF1AKDR | |
| SCHEMBL2619524 | 0.93 | HTR2A (0.53) | HTR2AHTR2CMCHR1KCNH2 | |
| SCHEMBL10287580 | 0.93 | HTR2A (0.51) | HTR2AHTR2CKDRKCNH2 | |
| SCHEMBL12214766 | 0.93 | HTR2A (0.51) | HTR2AHTR2CMCHR1KCNH2 | |
| SCHEMBL1017067 | 0.91 | KDR (0.49) | HTR2AHTR2CMCHR1ASF1AKDR | |
| SCHEMBL1018146 | 0.90 | KDR (0.48) | HTR2AHTR2CMCHR1KDR | |
| SCHEMBL10287582 | 0.90 | HTR2A (0.42) | HTR2AHTR2CKCNH2 | |
| SCHEMBL12727325 | 0.89 | HTR2A (0.51) | HTR2AHTR2CMCHR1KCNH2 | |
| SCHEMBL1071057 | 0.88 | KDR (0.46) | HTR2AHTR2CMCHR1ASF1AKDR | |
| SCHEMBL12727319 | 0.86 | MAPT (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281089-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281089-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | HTR2A 2634/4885HTR2C 2473/4885MCHR1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.